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Abstract: Marine organisms are recognized as a source of compounds with interesting biological
activities. Vibrio neocaledonicus has been reported on for its high effectiveness against corrosion
in metals but it has been little studied for its chemical and biological activities. In this study,
four compounds were isolated from V. neocaledonicus: indole (1); 1H-indole-3-carboxaldehyde
(2); 4-hydroxybenzaldehyde (3) and Cyclo (-Pro-Tyr) (4); using a bioassay-guided method, since
in a previous study it was found that the ethyl acetate extract was active on the enzymes
acetylcholinesterase (AChE), alpha-glucosidase (AG) and xanthine oxidase (XO). The inhibitory
activities of the three compounds against AChE, AG and XO was also evaluated. In addition,
the enzymatic inhibitory activity of indole to the toxins from the venom of Bothrops asper was tested.
Results showed that indole exhibited strong inhibitory activity to AG (IC50 = 18.65 ± 1.1 µM), to AChE,
and XO (51.3% and 44.3% at 50 µg/mL, respectively). 1H-indole-3-carboxaldehyde displayed strong
activity to XO (IC50 = 13.36 ± 0.39 µM). 4-hydroxybenzaldehyde showed moderate activity to XO
(50.75% at 50 µg/mL) and weak activity to AChE (25.7% at 50 µg/mL). Furthermore, indole showed
a significant in vitro inhibition to the coagulant effect induced by 1.0 µg of venom. The findings
were supported by molecular docking. This is the first comprehensive report on the chemistry of
V. neocaledonicus and the bioactivity of its metabolites.
Keywords: Vibrio neocaledonicus; acetylcholinesterase (AChE); alphaglucosidase (AG); xanthine
oxidase (XO); indole; bioactive compounds; snake venom
1. Introduction
Humans are affected by multiple diseases to which researchers are seeking effective and adequate
cures. Some of these diseases such as Alzheimer’s disease, diabetes and gout (caused by hyperuricemia)
are chronic diseases, which could be harmful to health and even life threatening. The synthesized
medicines currently used to treat the aforementioned diseases have some side effects and unwanted
adverse reactions, which directly affect the health of patients. Consequently, it is important and
necessary to find the active compounds in nature as drug leads. It is known that oceans, with high
concentrations of salt and low temperatures, provide an extreme environment for the microorganisms
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living in them, which force them to develop the capacity to produce special secondary metabolites
that help their adaptation. Abundant evidence has shown that marine bacteria in almost all parts of
the marine world, whether associated with other organisms or free-living, have developed different
strategies to survive in extreme environments [1]. It has been reported that coral-associated bacteria
have antimicrobial properties and act as antagonists against pathogens [2,3].
Bacteria belonging to the genus Vibrio consist of facultative aerobic and anaerobic gram-negative
species, which have a curved morphology, and are generally halodependent. V. neocaledonicus, has been
reported on for its corrosion inhibiting effect and this result is comparable with some industrial coatings,
since this bacterium affects corrosion by the formation of an inhibitory layer on the metal surface [4,5].
Even Vibrios bacteria are dominant in the marine environment with genomic flexibility, and they
have not been explored extensively. Some studies have reported that Vibrio bacteria could be the
producers of biologically active compounds with interesting antibacterial, anticancer and antiviral
properties [6]. We have conducted investigations in our laboratory on Vibrio spp. of the Vibrionaceae
family, particularly V. neocaledonicus, to explore the inhibitors for the acetylcholinesterase (AChE),
alpha-glucosidase (AG), and xanthine oxidase (XO), as well as the inhibitory substances for snake
venom [7].
Acetylcholinesterase inhibitors (AChEIs) can reduce the activity of the enzyme AChE that degrades
the neurotransmitter acetylcholine (ACh). ACh is essential for processing memory and learning. Both
the concentration and function of ACh are found to be decreased in patients with neuro degenerative
diseases like Alzheimer‘s disease. AChEIs may alter the cholinergic synapse, which is involved in
the etiology of Alzheimer’s disease [8]. A large number of compounds with varied structures from
natural sources have been found as potential AChEIs [9–11]. Although most of those compounds,
isolated from plants, algae, fungi, cyanobacteria, marine phytoplankton and marine sessile organisms
like sponges and soft corals, have been found to be important sources [12].
The search for new inhibitors of the XO and AG enzymes is urgent, due to their correlations with
painful diseases such as gout and diabetes, respectively. Urate is the final product of the reaction
catalyzed by XO. High levels of urate in blood cause gout, a painful joint disease. Some prescription
drugs like allopurinol can be used for the treatment of gout but with side effects such as allergic
reaction, gastrointestinal discomfort, diarrhea and drowsiness [13]. The inhibitors of the enzyme AG
are used to treat type 2 diabetes because they can lower blood sugar via decreasing the degradation
rate of carbohydrates after ingestion.
Snakebite envenoming kills more than 100,000 people and maims more than 400,000 people
every year [14]. Viperid snakes of the Bothrops genus inflict the majority of snakebites in Central
and South America [15]. The pathophysiological effects induced by snakebite envenomations from
Bothrops are induced by the biological activities of several enzymes, mainly phospholipases A2 (PLA2),
zinc dependent metalloproteinases (SVMPs) and serine proteinases (SVSPs) [16]. SVMPs induce
hemorrhage by the proteolytic degradation of endothelial cell surface proteins and extracellular
matrix components of capillaries and venules. PLA2 hydrolyze the sn2 ester bond of cell membrane
glycerophospholipids, inducing systemic and local myotoxicity, mionecrosis and edema. On the other
hand, SVSPs have been classified as activators of the fibrinolytic system, procoagulant, anticoagulant
and platelet-aggregating enzymes [17,18]. Therapy for snakebite envenomation is mainly based on the
intravenous administration of antivenoms [19,20]. However, it has been demonstrated that antivenoms
have a limited efficacy against the local tissue damaging activities of venoms [21,22]. Efforts are
made to search for alternative sources of venom inhibitors, either synthetic or natural, that would
complement the action of antivenoms, for the inhibition of toxins that induce local tissue damage,
such as PLA2s and SVMPs.
In an attempt to explore the biological and chemical aspects of V. neocaledonicus, we analyzed two
extracts from the same strain but from two different media (2216E and LB). On the other hand, snake
bite envenoming is a serious public health problem in many regions of the world. Therefore, we chose
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four objectives of our preliminary study in the search for bioactive inhibitory substances: AChE, AG,
XO and snake venom toxins.
Herein, we describe the identification of the active compounds from the ethyl acetate extract of V.
neocaledonicus. The production of compounds from two different media (2216E and LB) were compared
in the study, and the inhibitory activities of the compounds against the enzymes AG, AChE and XO,
as well as the protective properties against the indirect hemolytic, coagulant and proteolytic effects of
Bothrops asper venom were evaluated. This is the first comprehensive report of chemical investigation
on V. neocaledonicus and the enzymatic inhibition properties of the isolated chemicals, excluding two
patents applications about indole and indole-3-formaldehyde from V. neocaledonicus. [23,24].
2. Results
2.1. Culture Medium and Metabolite Production of Vibrio neocaledonicus
In order to compare the effect of different culture media on the production of metabolites of
V. neocaledonius, we carried out a qualitative thin layer chromatography (TLC) study to analyze the
ethyl acetate extract from the strains cultured in 2216E and Lysogeny broth L.B medium (liquid). From
Figure 1, the difference of the chemical pattern between fractionation A (extract obtained from medium
2216E) and fractionation B (extract obtained from LB medium) can be observed. The major compound
(indole) appeared in fractionation A and it was used as a chemical marker in fractionation B, whereas
we did not observe it in the plate corresponding to the second extract (Figure 1B). The plates were
revealed with p-anisaldehyde and different colors were observed that correspond mainly to phenolic
compounds, terpenes, flavonoids, flavanones. The anisaldehyde with sulfuric acid allowed us to
visualize, among other compounds, terpenoids, polypropanoids, saponins and phenolic compounds.
In the violet and red colors, terpenoids can be observed, flavonoids in yellow, and phenolic compounds
in the brown color (Figure 1A,B).
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Figure 1. Thin layer chromatography (TLC) of fractions with mobile phase hexane-acetone (7:3)
for comparison of the chemical differences between the first (A) and the second (B) cultures of
V. neocaledonicus.
2.2. Structural Elucidation
Chromatographic separation of the ethyl acetate extracts of V. neocaledonicus afforded four
compounds (Figure 2). Structure elucidation of all compounds was performed by 1D and 2D NMR
(results were shown in attachment), and confirmed by comparison with the data from the literature.
The compounds were identified as indole [25] (1) with the molecular formula C8H7N,
4-hydroxybenzaldehyde [26] (2) with C7H6O2, 1H-indole-3-carboxaldehyde [27,28] (3) with C9H7NO,
and (3S,8aS)-3-[(4-hydroxyphenyl)methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
(Cyclo (-Pro-Tyr)) [29] (4) with C14H16N2O3. Compounds 1–4 are reported for first time from
this strain. NMR spectra are available in Supplementary Material.
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extract of V. neocaledonicus and  the  isolated compounds  indole; 4‐hydroxybenzaldehyde, and 1H‐
indole‐3‐carboxaldehyde at different doses are shown in Tables 1,2. 
Table 1. IC50 value of acetylcholinesterase (AChE), alpha‐glucosidase (AG) and xanthine oxidase (XO) 
inhibitory  activity  of  V.  neocaledonicus  extract  and  isolated  compounds  indole,  4‐
hydroxybenzaldehyde, and 1H‐indole‐3‐carboxaldehyde. AChEI—acetylcholinesterase inhibitors. 
Group  AchE (IC50 μM)  AG (IC50 μM)  XO (IC50 μM) 
Huperzine (positive control)  0.445  ‐  ‐ 
Acarbose (positive control)  ‐  387.21 ± 12.54  ‐ 
Allopurinol (positive control)  ‐  ‐  7.82 ± 0.12 
V. neocaledonicus extract  15.27 ± 0.07 μg/mL  53.52 ± 1.4 μg/mL  341 ± 2.53 μg/mL 
Indole  334.81 ± 13.12  18.65 ± 1.1  842.58 ± 16.73 
4‐hydroxybenzaldehyde  6892.25 ± 117.58  ‐  506.23 ± 16.01 
1H‐indole‐3‐carboxaldehyde  ‐  ‐  13.36 ± 0.39 
Table 2. Percentage  inhibitory activities, on AChE, AG and XO corresponding  to  the extract of V. 
neocaledonicus and three isolated compounds at different doses: Indole, 4‐hydroxybenzaldehyde and 
1H‐indole‐3‐carboxaldehyde. 
Group  Dose (μg/mL)  AChEI%  AGI%  XOI% 
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Figure 2. Chemical structures of metabolites isolated from Vibrio neocaledonicus.
2.3. In Vitro Acetylcholinesterase, Alphagluco idase and Xanthine Oxidase Inhibition Ass y
The results obtained from the inhibitory activity of AChE, AG and XO corresponding to
the extract f V. neocaledonicus and the isolated compounds indole; 4-hydroxybenzalde yde, and
1H-indole-3-carboxaldehyde at different doses are shown in Tables 1 and 2.
Table 1. IC50 value of acetylcholinesterase (AChE), alpha-glucosidase (AG) and xanthine oxidase (XO)
inhibitory activity of V. neocaledonicus extrac and isolated compounds in ole, 4-hydroxybe zalde yde,
and 1H-indole-3-carboxaldehyde. AChEI—acetylcholinesterase inhibitors.
Group AchE (IC50 µM) AG (IC50 µM) XO (IC50 µM)
Huperzine (positive control) 0.445 - -
Acarbose (positive control) - 387.21 ± 12.54 -
Allopurinol (positive control) - - 7.82 ± 0.12
V. neocaledonicus extract 15.27 ± 0.07 µg/mL 53.52 ± 1.4 µg/mL 341 ± 2.53 µg/mL
Indole 334.81 ± 13.12 18.65 ± 1.1 842.58 ± 16.73
4-hydroxybenzaldehyde 6892.25 ± 117.58 - 506.23 ± 16.01
1H-indole-3-carboxaldehyde - - 13.36 ± 0.39
Table 2. Percentage inhibitory activities, on AChE, AG and XO corresponding to the extract of
V. neocaledonicus and three isolated compounds at different doses: Indole, 4-hydroxybenzaldehyde
and 1H-indole-3-carboxaldehyde.
Group Dose (µg/mL) AChEI% AGI% XOI%
V. neocaledonicus extract 50 98.34 ± 0.52 *** 47.28 ± 0.18 26.11 ± 0.03
25 69.67 ± 0.6 ** 33.33 ± 0.95 25.54 ± 0.13
12.5 22.34 ± 0.56 31.77 ± 0.45 24.62 ± 0.2
6.25 15.1 ± 0.11 29.06 ± 0.26 22.49 ± 0.03
3.125 6.23 ± 0.1 8 24 ± 0.03 7.62 ± 0.17
Indole 50 51.3 ± 1.67 * 100 *** 44.30 ± 1.14
25 37.54 ± 1.26 94.4 ± 1.01 *** 25.17 ± 0.65
12.5 36.63 ± 1.04 85.49 ± 0.83 *** 22.07 ± 0.55
6.25 9.42 ± 0.07 81.49 ± 1.17 *** 17.77 ± 0.52
3.125 0 51.43 ± 1.06 * 15.01 ± 0.31
4-hydroxybenzaldehyde 50 25.7 ± 0.56 0 50.75 ± 0.50
25 14.26 ± 0.011 0 31.67 ± 0.52
12.5 6.55 ± 0.02 0 27.28 ± 0.27
6.25 4.21 ± 0.01 0 25.27 ± 0.19
3.125 0 0 17.39 ± 0.49
1H-indole-3-carboxaldehyde 50 0 0 100 ***
25 0 0 86.49 ± 0.89 ***
12.5 0 0 71.29 ± 0.99 ***
6.25 0 0 67.69 ± 0.34 **
3.125 0 0 61.14 ± 0.14 **
Significant differences were considered when the *** = p value < 0.001, ** = p value < 0.01, * = p value < 0.05 with
respect to control.
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Based on Table 2, the extract of V. neocaledonicus showed 98.34% and 69.67% inhibition of AChE
statistically significant at the two highest doses 50 and 25 µg/mL, respectively. For the other two
enzymes evaluated (AG and XO), percentages of inhibition were also presented in all the doses
used although they were not statistically significant. For the isolated compounds, both indole and
4-hydroxybenzaldehyde, showed moderate percentages of inhibition compared with the extract,
which suggests that the high inhibitory activity of the extract may be due to a synergy between the
components, although the percentages of inhibition of the compounds separately were not significant.
In addition, according to the data listed in Table 2, indole showed a strong dose-dependent inhibitory
activity against AG enzyme, with 94.4, 85.49, 81.49 and 51.43% inhibition at the doses 25, 12.5, 6.25, and
3.125 µg/mL, respectively. While 4-hydroxybenzaldehyde and 1H-indole-3-carboxaldehyde showed
no inhibitory activity for the enzyme AG at any of the tested doses.
In the XO inhibition bioassay, no activity was observed for indole and 4-hydroxybenzaldehyde.
However, the activity of 1H-indole-3-carboxaldehyde in all the doses analyzed was very high and
significant (100%, 86.49%, 71.29%, 67.69% and 61.14%) (Table 2).
2.4. Antiophidic Activities
2.4.1. Inhibition of Proteolytic Activity by Indole
When B. asper venom was pre-incubated with indole at varying ratios, inhibition of the proteolytic
activity of B. asper venom was observed (Figure 3A). The venom:compound ratio of 1:20 showed
proteolytic activity inhibition of 77.9% ± 5.5. These differences were statistically significant with respect
to the positive control. The venom:compound ratio 1:10 showed weak inhibition without significance.
Mar. Drugs 2019, 17, x  5  of  19 
 
  6.25  4.21 ± 0.01  0  25.27 ± 0.19 
  3.125  0  0  17.39 ± 0.49 
1H‐indole‐3‐carboxaldehyde  50  0  0  100 *** 
  25  0  0  86.49 ± 0.89 
*** 
  12.5  0  0  71.29 ± 0.99 
*** 
  6.25  0  0  67.69 ± 0.34 ** 




statistically significant at  the  two highest doses 50 and 25 μg/mL,  respectively. For  the other  two 
enzymes evaluated (AG and XO), percentages of inhibition were also presented in all the doses used 
although  they were  not  statistically  significant.  For  the  isolated  compounds,  both  indole  and  4‐
hydroxybenzaldehyde, showed moderate percentages of inhibition compared with the extract, which 
suggests  that  the  high  inhibitory  activity  of  the  extract may  be  due  to  a  synergy  between  the 
components,  although  the  percentages  of  inhibition  of  the  compounds  separately  were  not 









When  B.  asper  venom  was  pre‐incubated  with  indole  at  varying  ratios,  inhibition  of  the 
proteolytic activity of B. asper venom w s observed (Figure 3A). The venom:compound rati  of 1:20 
showed proteolytic activity inhibition of 77.9% ± 5.5. These differences were st istically significant 











Figure 3. Inhibition of the proteolytic activity of B. asper venom (A) and a metalloproteinase (B) by
indole. A dose of 3 µg of venom or toxin per well was used. *** = p value < 0.001, ** = p value < 0.01
with respect to positive control.
Likewise, the inhibitory capacity of indole on the proteolytic activity induced by a Metalloprotease
isolated de B. atrox was evaluated. When the toxin was pre-incubated with indole at varying
ratios, a low degree of inhibition of the proteolytic activity was observed (Figure 3B). The inhibition
showed dose-dependent behavior, 1:20 (20.61 ± 3.5); 1:10 (13.54 ± 2.5) and 1:5 (4.31 ± 1.9) (Figure 3B).
The inhibition at 1:5 was not significant compared to the control.
2.4.2. Inhibition of the Activity Coagulant by Indole
The compound indole, showed significant inhibition of the coagulating effect in vitro induced by
1.0 µg of venom, corresponding to a clotting time of 21.6 ± 0.8 s. Initially, the coagulant activity was
changed at low ratios of 1:5 (venom:compound w/w). However, the extension of the coagulation time
became statistically significant when the venom was used at a ratio of 1:10 and 1:20 with indole, with
the maximum delay times for clotting on set found to be 119.7 ± 10.7 s and 99 ± 4.0 s, respectively.
From this relationship, the inhibitory effect was shown to depend on the compound concentration.
Likewise, after half an hour of incubation, it was possible to validate that the compound relations used
for this trial did not generate coagulant activity by themselves (Figure 4).
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Figure 4. Inhibition of the complete venom coagulant activity of B. asper by indole. A dose of 1µg of
venom per tube was used. ** = p value < 0.01 with respect to positive control.
2.4.3. Inhibition of PLA2 Activity
To evaluate the activity of PLA2, two different techniques were applied: Indirect hemolytic activity
and the use of 4-nitro-3-octanoyloxybenzoic acid (4N3OBA) as monodispersed substrate. A low degree
of inhibition against PLA2 activity by indole was observed (Figure 5). The toxin:compound ratio of
1:20 showed proteolytic activity inhibition of 15.20%; while a ratio of 1:10 showed proteolytic activity
inhibition of 10.0%. These differences were not statistically significant between the evaluated ratios,
but they were significant with respect to the positive control (Figure 5). Indole did not show inhibition
of the indirect hemolytic activity of the complete venom of B. asper at tested doses.
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Figure 5. Inhibition of PLA2 activity by indole. A dose of 7 µg of pure toxin. There is no significant
inhibition against PLA2 activity. *** = p value < 0.001, ** = p value < 0.01 with respect to positive control.
2.5. Molecular Docking Studies
In order to get the possible mode of inhibition of AChE and AG by indole, and XO by
1H-ind le-3-carboxaldehyde, molecular docking simulations were performed. Docked soluti ns
with the lowest binding ene gies were selected and the r sults obtained are s mmarized in Tabl 3.
These results suggest that indole 1H-i dole-3-carboxaldehy e may occupy the AChE, AG a XO
activ site (Table 3 and Figures 6 and 7).
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Table 3. Interactions and affinities of indole with active-site residues of the AChE and AG, and 1H-indole-3-carboxaldehydewith active-site residues of the XO.
Enzyme Ligand Interactions Affinity (Kcal/mol)
Hydrogen bonds Van der Waals π − πstacked π-anion π − π T-shaped π-alkyl
AChE (PDB
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Figure 6. Molecular docking. (A) Indole with active site residues of AChE (B) Indole with active site
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3. Discussion
The chemical study of V. neocaledonicus allowed the identification of indole (1) as one of the
major compounds responsible of the inhibitory activity of AChE and AG. In addition, other three
compounds were isolated and identified as 4-hydroxybenzaldehyde (2), 1H-indole-3-carboxaldehyde
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(3) and Cyclo (l-Pro-l-Tyr) (4), which may contribute to an increase in knowledge of the chemistry on
V. neocaledonicus.
Despite the narrow structural margin reported for vibrios, compared to metabolites produced by
other marine bacteria, vibrios produce compounds with a wide range of interesting biological activities
including antibacterial, anticancer and antiviral activities [6]; a clear example being the V. neocaledonicus
species of the present study. The production of compounds from microorganisms is regulated by many
factors, such as the sources of carbon, nitrogen, phosphorus and oxygen in the medium as well as the
temperature, pH, and agitation. Such cultivation conditions are a key element for the discovery and
production of secondary metabolites as they can activate or deactivate different biosynthetic routes [30].
From this fact, it is of paramount importance to know the ecological functions of these metabolites,
as well as the specific conditions in which their biosynthesis is given, in order to understand and to
manage the production of those compounds in in vitro conditions [31,32]. There are some examples
where the concentration of phosphates and availability of nitrogen sources can affect the production of
compounds [33,34]. These qualitative differences among extracts of the same strain can be explained
by the variances between the composition of the medium in relation to the content of nitrogen and
phosphorus, which then affected the production of metabolites in V. neocaledonicus (Figure 1). We found
that V. neocaledonicus produced indole with a fairly high yield (9.20%) in the culture made with liquid
medium 2216E. There are reports that many species of bacteria can produce indole [35], however,
despite the high energy cost that this represents for bacteria, it is still not clear why they produce large
quantities of this compound.
According to Lee and Lee [35], indole is an intercellular signal chemical in gram positive (+) and
gram negative (-) bacteria and has been shown to control a number of bacterial processes such as spore
formation, plasmid stability, drug resistance, biofilm formation, and virulence. Moreover, it has been
reported that indole can form dimers through carbon-carbon, carbon-nitrogen, or nitrogen-nitrogen
linkage to form a small class of biindol marine alkaloids with cytotoxicity against cancer cell lines [36].
Likewise, Atanasova [37], reported the design and prediction of new derivatives of galantamine with
the indole molecule in the lateral chain to inhibit the activity of the enzyme AChE. The inhibitory
activity AG of indole is comparable with the activity of Acarbose (Tables 1 and 2) which is one of the
drugs used for diabetes. The above indicates the great potential of this compound for the treatment of
diabetes. On the other hand, taking into account that this species can produce high amounts of indole
under certain growing conditions, it is possible to produce indole by cultivating this strain on a large
scale, without causing environmental problems, in a sustainable and economic way. Additionally,
the data that support the strong activity of indole against enzyme AG relate to its chemical structure.
According to Kim [38], there are three types of inhibitors for AG based on its chemical structure:
N-substituted heterocyclic poly-hydroxy; Cycle-alkenes poly-Hydroxyl and Oligomers pseudo sugars.
Indole is an N-substituted aromatic heterocyclic organic compound. At a pharmacological level, within
the natural inhibitors of this enzyme, there are compounds of bacterial origin such as acarbose, miglitol
and voglibose (hemi-synthetic) [39], and these are active ingredients in anti-diabetes drugs for type II
diabetes [40].
4-hydroxybenzaldehyde (2), an analog of p-hydroxybenzyl alcohol, showed a slight inhibitory
effect on AChE and XO. Its antiepileptic and anticonvulsant activity has been reported as being even
greater than that of valproic acid, a known anticonvulsant [41]. In addition, 4-hydroxybenzaldehyde
derivatives have been synthesized and investigated for their inhibitory effects on fungal tyrosinase and
Gamma Amino-Butyric Acid GABA-derived enzymes [42]. 1H-indole-3-carboxaldehyde (3) exhibited
a very strong inhibitory activity to XO (IC50 13.36 ± 0.39 µM). The results obtained from this study
are comparable with other known XO inhibitors such as Allopurinol, an analogue of hypoxanthine
for the treatment of gout, and other compounds with the same activity reported such as Febuxostat.
In spite of the fact that the mechanism of action of indole-3-carboxaldehyde is not well understood,
it is interesting to analyze the mechanism of action of allopurinol (our positive control) to try to give an
application to the action of this compound (3). First, Allopurinol acts as a substrate and subsequently
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as an inhibitor of XO. The oxidase hydroxylates allopurinol to form alloxanthin, which is then tightly
bound to the active center. The binding of alloxanthin keeps the molybdenum atom of the enzyme in a
+4 oxidation state, preventing it from returning to the +6 oxidation state, just as it would in a normal
catalytic cycle. This type of inhibition is known as "suicidal inhibition" and could be a hint to elucidate
the mechanism of action of indole-3-carboxaldehyde (3). Interestingly, some indole-3-carboxaldehyde
derivatives have been reported in terms of synthesis and antimicrobial activity (antibacterial, antifungal
and antiamebian) [43,44].
The compound Cyclo (L-Pro-L-Tyr) (4) was not evaluated for bioactivities due to the low quantity
obtained; however, this compound is reported for the first time for the strain. In addition, small
molecules isolated from the species of genus Vibrio that induce gram-negative quorum sensing systems
(QS) detection have been reported, and some of the molecules possess a group of diketopiperazines
(DKP), for example, cycle (L-Pro, L-Leu), cycle (L-Pro, L-Val) and cycle (L-Pro, L-Tyr) [45]. On the one
hand, it is likely that these dipeptides represent a new class of naturally occurring QS signals that can
participate in interspecific signaling, since DKPs are found in most culturable marine bacteria [46];
however, it is also possible that some DKPs are generated from media components during processing
procedures [47].
Snake venom is designed to immobilize, kill and help digest prey. It is made up of different toxins
that can be grouped into a small number of major protein families, including phospholipase A2 (PLA2),
zinc-dependent metalloproteinases, serineproteases, C-type lectin proteins, disintegrins, cysteine
rich proteins (CRISPs), bradykinin potentiating peptides and l-aminoacidoxidase, and others [48].
Consequently, viper snakebites characteristically cause local and systemic pathological changes, such
as coagulation disorders, systemic hemorrhage, necrosis, thrombocytopenia, pain and edema, which
may vary in intensity depending on the species, age and size of snake [48,49]. The neutralization of
all these effects by anti-venoms is a difficult task. However, the microorganisms represent potential
sources of inhibitors and could be an alternative for tackling this problem. In this study, indole isolated
from V. neocaledonicus, showed an inhibitory capacity to the toxic activities of B. asper venom in an
in vitro model. B. asper venom affects blood coagulation by allowing the formation of fibrin from
fibrinogen due to the presence of toxins that activate platelets and factor XII, whereas the molecular
factors V and VI found in the venom directly activate factor X. As fibrinogen is converted to fibrin,
it becomes more unstable and susceptible to lysis by natural fibrinolytic systems [20]. As shown in
Figure 4, indole showed a greater extension of the clotting time, the delay in coagulation was effective
in neutralizing the coagulating effect when administered in a ratio of 1:10 and 1:20 (119.7 ± 10.7 s
and 99 ± 4.0 s respectively). So, indole has the potential to interact with serine proteinases; these
enzymes are present in the venom and are responsible for its plasma coagulation effect. Certainly,
indole also showed some degree of inhibition of other activities of the venom such as proteolytic
activity (Figure 3A,B) and hemolytic activity (Figure 5). Although the results were not statistically
significant, it is important to mention that the compound has the ability to interact with the toxins
responsible for these effects (Metalloprotease and PLA2).
The experimental results in the in vitro model correlate well with the molecular coupling data
results (Figures 6 and 7). Figure 6A showed that hydrogen bond and π − π stacked interactions
between indole and AChE could block binding of the quaternary trimethylammonium tail group of
ACh, given that the “anionic” subsite of the enzyme is formed by side chains of Glu202, Trp86 and
Tyr337. Similarly, π − π stacked interactions with Gly121 could block the oxyanion hole [50]. The
active site of all xanthine-utilizing enzymes has a conserved arginine residue (Arg880 in the bovine
enzyme), and it has been proposed that this residue contributes to transition state stabilization. On the
other hand, Glu802 facilitates xantine tautomerization and thus contributes to rate acceleration [51].
Thus, hydrogen bonds between Arg880, Glu802 and 1H-indole-3-carboxaldehyde could negatively
affect enzymatic catalysis (Figure 6C, Table 2).
It has been reported that AG uses a double-displacement reaction mechanism in which aminoacids
Asp518 and Asp616 act as catalytic nucleophile and acid/base [52]. Thus, according to Figure 6B,
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hydrogen bonds between indole with Asp616, and π -anion interactions between indole with Asp518,
could inhibit the catalytic cycle of AG. Otherwise, Van der Waals interactions involving Indole and the
amino acids that belonged to the hydrophobic pocket, such as, Trp376, Trp516, and Trp613 [53] could
enhance the inhibitory effect (Figure 6B, Table 2).
These results suggested the potential feasibility of V. neocaledonicus. It is important to focus
efforts on the search for AChE, XO and AG inhibitors from natural sources; perhaps several potential
inhibitors in marine bacteria are waiting to be discovered to provide easily manipulated natural
sources for the mass production of these therapeutic compounds. This fact indicates that the marine
organisms have a high potential for the discovery of new and valuable compounds with diverse grade
of pharmaceutical applications.
4. Materials and Methods
4.1. Sample and Reagents
Acetylcholinesterase from Electrophorus electricus, alphaglucosidase from Saccharomyces cerevisiae,
and xanthine oxidase from bovine milk were obtained from Sigma Aldrich (Shanghai, China). The other
reagents used in the bioassays were purchased either from Solarbio or Sigma Aldrich. Analytical
reagent grade organic solvents for extraction were purchased from XL Xilong Scientific Chemical. Silica
gel plates (Silica gel 60 F254 0.2 mm layer thickness) were purchased from Merck (KGaA, Darmstadt,
Germany). A spectrometer (Thermo Scientific Multiskan GO, Vantaa, Finland) was used for all
measurements of AChE, AG and XO inhibitory activities. The venom was extracted and collected
manually from the adult specimens of B. asper snakes from Colombia (South America) that were
held captive in the Serpentarium at University of Antioquia. The venom was centrifuged, and the
supernatant was lyophilized and frozen at −70 ◦C until its use.
Column chromatography was carried out on silica gel (50–80 Size A◦ Qingdao Bangkai Hi-tech
Materials, Shandong, China) and TLC (TLC Silica gel 60 F254 aluminum sheets) was used to monitor
the fractions from the column chromatography. Preparative TLC was carried out on glass sheets (Silica
gel GF254 20 × 20 cm, 0.9–1.0 mm Qingdao Bangkai Hi-tech Materials). Visualization of the TLC plates
was achieved by using a UV lamp (λ 14 254 and 365 nm) or/and spraying p-Anisaldehyde (Aladdin
Industrial Corporation, Hangzhou, China) reagent then heating at 105 ◦C for 1 min. 1H and 13C NMR
spectra were measured on a Bruker AMX 500 MHz NMR spectrometer with standard pulse sequences,
operating at 500 MHz for 1H and 125 MHz for 13C.
4.2. Marine Bacterial Strain
V. neocaledonicus was obtained using the traditional methods of farming. The strain was isolated
from coral reef in South China Sea, and characterized and identified using both conventional molecular
methods (16S rRNA gene sequencing) based on its morphological characteristics. The voucher number
for the organism is CCTCC M2017802. The isolated strain was preserved in a marine medium Difco
2216 semi-solid at 4 ◦C until it was used for cultivation.
In this study, two types of cultures using the same strain (V. neocaledonicus) were made with
two different media. The first crop was made with V. neocaledonicus cultivated (8.0 L) in 2216E
Liquid Medium (Qingdao Hope Bio-Tecnhology Co, Shandong, China) for 10 days at 30 ◦C with
stirring at 160 rpm. The 2216E culture medium (37.4 g/1000 mL of distillated water) was subjected
to autoclaving. For the second culture, V. neocaledonicus was cultivated (16 L) with LB medium,
in which 10.0 g of Tryptone (LP0042 – OXOID), 5.0 g of Yeast extract (LP0021 – OXOID) and 20.8 g
of NaCl, (A.R. Guangzhou chemical reagent factory, Guangzhou, China) were used. The bacteria
were left to grow for 10 days at 30 ◦C with stirring at 160 rpm. The water used was distilled through
equipment AXL Water. All means and instruments used in microbiology were sterilized with steam in
an autoclave (Zealway autoclave-GI54DW, 32 L) under 20 psi and at 121 ◦C for 20 min. The innocuous
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ones were prepared in cabin flow laminar ZJ (SW-CJ-1D). Incubation of agar plates was conducted in a
ZHWY-2112B Incubator shaker at 30 ◦C.
4.3. Extraction Process
For each of the two crops of V. neocaledonicus in two different media, the following procedure was
carried out for extraction: biomass was separated by centrifugation at 8000 rpm for 10 min at 29 ◦C on
a centrifuge (Thermo Scientific Heraeus Multifuge X3R, Osterode am Harz, Germany). Subsequently,
the supernatant was filtered out and the strain was subjected to maceration with ethyl acetate (1 L × 3
times), then concentrated by using an IKA-HB10 rotary-evaporator under reduced pressure in with a
compact vacuum pump MVP 10. The extracts were evaluated using the bioassays for AChEI, AGI and
XOI activity.
4.4. Isolation of Secondary Metabolites from Vibrio neocaledonicus
For the first culture, ethyl acetate extract (1.2 g) was fractionated by column chromatography
(CC) (3 × 50 cm) on silica gel, eluting sequentially with the following solvents mixtures: hexane,
hexane-ethyl acetate (7:3), hexane-ethyl acetate (5:5), ethyl acetate, ethyl acetate-methanol (7:3), ethyl
acetate-methanol (1:1), methanol. The following spray reagents were used in order to develop the
spots: anisaldehyde-sulphuric acid (sterols, phenolic compounds, terpenes), also the plates were
revealed with reagent of Draggerdorf to look for presence of alkaloids. According to the behavior on
the TLC, the elutes were grouped into eight fractions (F1 to F8): F1 (0.008 g), F2 (0.002 g), F3 (0.198 g),
F4 (0.017 g), F5 (0.019 g), F6 (0.027 g), F7 (0.198 g), and F8 (0.531 g). Fraction F3 was separated by CC on
silica gel eluting with hexane-acetone (8:2). Subfraction F3.2 (128.8 mg) was further separated by CC
eluting with hexane-acetone from 9:1 to 1:1 to offer compound 1 (110.0 mg). Fraction F1 (0.008 g) no
color, not active resulted in AChI and AgI bioassay. Fraction F2 (0.002 g) no color, not active resulted in
AChI and AgI bioassay. Fraction F3 (0.198 g) brown color, showed activity in AChI and AgI bioassay,
was fractionated. We obtained seven sub-fractions (F3.1-F3.7), being the fraction F3.2 (128.8 mg) with
strong activity AChI and was fractionated by CC. We obtained eight sub fractions (3.2.1-3.2.8) being
the fraction 3.2.2 (57.4 mg) and 3.2.3 (52.7 mg) active in AChI and AgI bioassay. A part of fraction 3.2.2
(3.2 mg) was sent to analyze by NMR. Fraction F4 (0.017 g) in a brown color showed no activity in
AChI but strong activity in the AgI bioassay. A CPP was made and three subfractions were obtained.
Subfraction 4.1 and 4.2 were send for NMR analysis. Fraction F5 (0.019 g) presented no activity in
AChI but was active in AgI bioassay. Then a CPP was made. We obtained five fractions (F5.1–F5.5).
Subfraction 5.1, 5.2 and 5.3 were sent for NMR analysis. Fraction F6 (0.027 g) in a dark brown color
showed low activity in AChI but strong activity in the AgI bioassay. It was fractionated. We obtained
four fractions (F6.1–F6.4), subfraction F6.2 (15 mg) was fractionated and we obtained three fractions
F6.2.1–F6.2.3. The subfraction 6.2.3 was fractionated by C.C with hexane-acetone. Fraction F7 (0.198 g)
in a dark color presented good activity in AChI and low activity in AgI bioassay. Was fractionated by
C.C. We obtained three fractions (F7.1-F7.3); making the fraction 7.3 (61.3 mg) with good activity AChI.
Fraction 7.3 was fractionated and five sub fractions were obtained (7.3.1–7.3.5) making the fraction
7.3.2 (1.5 mg), which was active in the AChI bioassay and was sent to be analyzed by NMR. Fraction
7.3.4 (30 mg) was active in the AChI bioassay. Fraction F8 (0.531 g) in a dark color, presented good
activity in AChI and low activity in the AgI bioassay. Fraction F8.4 (100.3 mg) was active in AChI and
was fractionated. We obtained three sub fractions (8.4.1–8.4.3) being the fraction 8.4.3 (28.7 mg) active
in AChI and was purified by CCP. Subfractions 8.4.3.1A, 8.4.3.1B and 8.4.3.1C were active in AChI
bioassay and they were sent for NMR analysis.
For the second culture, ethyl acetate extract (3.6 g) was fractionated by CC on silica gel eluting
sequentially with hexane, hexane-ethyl acetate from 9:1 to 1:1, ethyl acetate, ethyl acetate-methanol (9:1),
ethyl acetate-methanol (7:3), ethyl acetate-methanol (1:1) and methanol. According to the behavior on
the TLC, the elutes were grouped into seven fractions (F1 to F7): F1 (0.0202 g), F2 (0.0047 g), F3 (0.180 g),
F4 (0.030 g), F5 (0.025 g), F6 (0.091 g) and F7 (1.7 g). Fraction F5 was purified by using a preparative
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TLC plate with hexane-acetone (7:3) as mobile phase to give compound 2 (6.5 mg). Fraction F6 (91.0 mg)
was separated by CC on silica gel eluting with a mixture of hexane-acetone from 7:3 to 1:1, then acetone
and methanol. Subfraction F6.2 (53.0 mg) was fractionated by CC eluting with hexane:acetone from
7:3 to 1:1 to give subfraction 6.2.1 (35.2 mg), which was subjected to being purified on a preparative
TLC plate with hexane-acetone 6:4 as mobile phase to afford compound 3 (10.0 mg) of. Fraction F7
(1700 mg) was separated by CC on silica gel eluting with dichloromethane-methanol from 9:1 to 1:1
to give the subfraction 7.5.1 (12.2 mg), which was further purified on a preparative TLC plate with
dichloromethane-methanol 9:1 to provide compound 4 (4.3 mg).
1H and 13C NMR spectra were obtained on a Bruker model AMX 500 MHz NMR spectrometer
with standard pulse sequences. The chemical shift values were reported in parts per million units
(ppm) from tetramethyl silane as standard reference. Coupling constants were calculated in hertz
(Hz). The 2D NMR spectra including COSY, HMQC and HMBC were measured using the standard
pulse sequences.
4.5. Acetylcholinesterase Inhibition Assay
The extracts and compounds 1–3 isolated from V. neocaledonicus were submitted for bioassay.
AChE inhibition was determined according to the method of Ellman [54] with ATCI as substrate.
In short, to a 96-well microplate, 20 µL of 0.30 mg/mL ATCI, 10 µL of different concentrations (ranging
from 3.125–50 µg/mL) of sample solution (extract or compound dissolved in 2% of DMSO and PBS),
10 µL of 1.0 µg/mL AChE, 40 µL of 0.02 mol/LPBS (pH 7.4), after incubation at 37 ◦C for 30 m, 20 µL
4% SDS was added to stop the reaction. Then, 100 µL of 0.59 mg/mL DTNB was added to produce
the color, the OD was measured at 405 nm in spectrometer. All determinations were performed in
triplicate with Huperzine as positive control. The control contained all components except the tested
extract. The inhibitory rate was calculated as the formula: %I = [1 − (ODs−OD sample sb)/ODn-ODnb]
× 100%; where: ODn is the absorbance value of the sample system in which sample is substituted by
PBS, ODnb is the absorbance value of ODn in which no AChE was added, ODsb is the absorbance of
ODs in which no AchE was added.
4.6. Alphaglucosidase Inhibition Assay
Extracts and compounds 1–3 isolated, from V. neocaledonicus, were submitted for bioassay.
The AG inhibition activity was evaluated by measuring the release of p-nitrophenol from p
nitrophenyl-α-d-glucopyranoside (pNPG) following the protocol proposed by Pistia-Brueggemann [55],
with modifications. The assay contained 80 µL of phosphate buffer (PBS 0.5 M, pH 6.8); 10 µL of
l-Glutathione (reduced-Solarbio Life Sciences) solution to protect the enzyme, 20 µL of enzyme, 20 µL
of α-glucosidase (1 UI/mL, derived from S. cerevisiae); 20 µL of different concentrations (ranging from
3.125–50 µg/mL) of sample solution (extract or compound dissolved in 2% of DMSO and PBS); 40 µL
of pNPG (11.3 mM). The control (C-) contained all the reagents but the sample was substituted by PBS.
All determinations were carried out in triplicate with Acarbose as positive control. The absorbance
was read after incubation for 30 min at 37 ◦C in a spectrometer Thermo Scientific Multiskan GO
reader at 405 nm. The inhibitory rate was calculated as the formula: %I = [1 − (ODs − OD sample
sb)/ODn-ODnb] × 100%; where: ODn is the absorbance value of the sample system in which sample is
substituted by PBS, ODnb is the absorbance value of ODn in which no AG was added, ODsb is the
absorbance of ODs in which no AG was added.
4.7. Xanthine Oxidase Inhibition Assay
Extract and compounds 1–3 isolated, from V. neocaledonicus, were submitted for bioassay. The
assay was based on the developed method of Valentao [56] and modified for application in microplates
by Lopez-Cruz [57]. All test samples were dissolved in a 50 mM phosphate buffer to simulate
the environment in which the reaction occurs in the body. Different concentrations (ranging from
3.125–50 µg/mL) of sample solution (extract or compound dissolved in 2% of DMSO and PBS). Finally,
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0.5 U/mL of enzyme XO solution was added and the absorbance was recorded at 295 nm. Allopurinol
1.2 mmol /L was used as a positive control. The control contained all components except the sample.
The inhibitory rate was calculated as the formula: %I = [1 − (ODs − OD sample sb)/ODn-ODnb] ×
100%; where: ODn is the absorbance value of the sample system in which sample is substituted by
PBS, ODnb is the absorbance value of ODn in which no XO was added, ODsb is the absorbance of ODs
in which no XO was added.
4.8. Antiophidic Activity
4.8.1. Purification of the Metalloproteinase (Batx-I) and Phospholipase A2 (Cdcum6)
Batx-I was isolated from Bothrops atrox according to the protocol of Patiño [58]. Purification
was done by ion-exchange chromatography (CM Sephadex C25) and the toxin purity was tested
by RP-HPLC and SDS PAGE. PLA2 was isolated from Crotalus durissus cumanensis according to the
protocol of Pereañez [59]. PLA2 was purified by RP-HPLC on C-18 column eluted at 1.0 mL/min with
a gradient from 0% to 100% acetonitrile in 0.1% trifluoroacetic acid (v/v). Absorbance was monitored
at 215 nm. Batx-I and Cdcum6 were lyophilized and stored at −20 ◦C until their use.
4.8.2. Inhibition of PLA2 Activity
The inhibitory effect of indole on the PLA2 of snake venom was assessed by two methods; the first
of them, using monodispersed substrate 4N3OBA (manufactured by BIOMOL, Hamburg Germany)
according to the method described by Holzer and Mackessy [60] and adapted for a 96-well ELISA
plate. The standard assay contained 200 µL of buffer (10 mM Tris–HCl, 10 mM CaCl2, 100 mM NaCl,
pH 8.0), 20 µL of 10 mM of substrate (4NO3BA), 20 µL of sample (20 µg PLA2 or 20 µg PLA2 + several
concentrations of indole) and 20 µL of water. The negative control was only buffer. The inhibitory
effect of indole on PLA2 activity was determined through pre-incubation of the enzyme with each
concentration of the compound for 30 min at 37 ◦C. After the incubation period, the sample was added
to the assay and the reaction was monitored at 425 nm for 40 min at 37 ◦C. The quantity of chromophore
released (4-nitro-3-hydroxy benzoic acid) was proportional to the enzymatic activity. The results are
indicated as inhibition percentages.
The second method to evaluate the inhibitory effect of indole on PLA2, was determining the
inhibition of the indirect hemolytic activity. This was evaluated in agarose-erythrocyte-egg yolk gels
according to Gutierrez [61]. It used a minimum indirect hemolytic dose (MIHD) of B. asper venom
of 2.2 µg, defined as the amount of venom that induced a 20 mm diameter hemolytic halo. Venom
and different doses of indole were preincubated for 30 min at 37 ◦C and the inhibitory potential was
measured after 20 h of plate incubation at 37 ◦C. This experiment was done in triplicate.
4.8.3. Inhibition of Coagulant Activity
The method described by Theakston and Reid [62] was followed, with small modifications. Briefly,
1.0 µg of B. asper dissolved in 25 µL PBS were mixed with 75 µL of different concentrations of indole,
and pre-incubated for 30 min at 37 ◦C. After, 100 µL of mixtures were added to 0.2 mL of plasma, and
the time required for plasma coagulation was determined.
4.8.4. Inhibition of Proteolytic Activity
The proteolytic activity was measured on azocasein (Sigma Aldrich, St. Lous, MO, USA) according
to Wang [63] with some modifications. Briefly, 3 µg of B. asper venom or Batx-I were dissolved in 5 µL
of 25 mM Tris (0.15 M NaCl, 5 mM CaCl2), pH 7.4, and were mixed with different doses of indole in
order to obtain 1:20, 1:10 and 1:5 w/w ratios, respectively. Mixes were pre-incubated for 30 min at 37 ◦C.
Later, these solutions were incubated with 10 mg/mL of azocasein diluted in the same buffer. After an
incubation of 90 min at 37 ◦C, the reaction was stopped by the addition of 200 µL of trichloroacetic
acid. The samples were then centrifuged at 3000 rpm for 5 min. The supernatant (100 µL) was mixed
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with an equal volume of 0.5 M NaOH, and the absorbance was measured at 450 nm. Results are shown
as percentage of activity (absorbance at 450 nm). The assay was carried out in triplicate.
4.9. Molecular Docking Studies
The software Avogadro 1.2 [64] was used to build the indole and 1H-indole-3-carboxaldehyde and
to improve its overall structure by an energy minimization process based on the MMF94 force field by
means of a steepest-descent algorithm in 500 steps. Molecular docking was carried out on a personal
computer using AutodockVina [65]. The protein pdb codes were 4PQE, 5NN8 and 3NVY for AChE,
AG and XO, respectively. The structure was refined on the WHAT IF package [66] to correct errors
from the experimental output such as missing atoms and undesirable location of side chains. Proteins
were used without water molecules. The structures of the proteins were prepared using the Protein
Preparation module implemented in the Maestro program. First, hydrogen atoms were automatically
added to each protein according to the chemical nature of each amino acid, based on the ionized
form expected in physiological condition. This module also controls the atomic charges assignment.
Second, each 3D structure of the protein was relaxed through constrained local minimization, using
the Optimized Potentials for Liquid Simulations (OPLS) force fields to remove possible structural
mismatches due to the automatic procedure employed to add the hydrogen atoms. The grid size for
each receptor was 24 Å3 and the grid centers were X = 33.6, Y = 19.8, Z = 12.3; X = −28.2, Y = −23.8,
Z = 1.4; X = −18.8, Y = −24.5, Z = 99.6 for 3NVY, 4PQE and 5NN8, respectively. The receptor grid was
generated by identification of active site residues. Exhaustiveness = 20. Then, the ligand poses with
best affinity were chosen, and a visual inspection of the interactions at the active site was performed
and recorded. The open functionalities of the Discovery Studio 4.0® package by Accelyrs and UCSF
Chimera (www.cgl.ucsf.edu/chimera/) were used to generate docking images.
4.10. Statistical Analysis
In order to determine significant differences among the concentrations of extract or compound used
in the enzymes inhibition assays, the results were analyzed using one-way ANOVA non parametric
Kruskal Wallis with Bonferroni post-test. Significant differences were considered when the p values
were at least p ≤ 0.001. Results are shown as mean x ± SEM of n indicated in each case.
5. Conclusions
In conclusion, we present here a study to identify bioactive compounds isolated from marine
bacterium V. neocaledonicus and their enzyme inhibitory activities. The compounds isolated from this
species, particularly indole, are potential inhibitors of enzymes. The results of the molecular coupling
for the isolated main compound (indole) show the interesting inhibitory potential to AChE, AG, XO
and myotoxic PLA2s. More tangible evidence of its usefulness is required, such as the design and
testing of derivatives, whose results could guide the development of an AChE inhibitor. Our results
suggest that indole could interact with the active site and other regions of the AChE and AG enzymes,
blocking its catalytic cycle and substrates binding. Additionally, this is the first comprehensive report
of a chemical study of V. neocaledonicus in China. Future studies should be related to the continuation
of the isolation of the secondary metabolites of V. neocaledonicus, in addition to the exploration and
elucidation of the mechanism of action of the compound or compounds responsible for the evaluated
activities. In the future, it might be important to extend the sequencing of the vibrios complete genome
and to investigate the prevalence of biosynthetic genes linked to secondary metabolism to contribute,
in general, to the knowledge of the ecological roles of these bacteria and the environmental and
physiological factors that regulate the production of their secondary metabolites.
Supplementary Materials: The following resources are available online at http://www.mdpi.com/1660-3397/
17/7/401/s1, Figure S1: NMR Indole, Figure S2: NMR 4-hydroxy-benzaldehyde, Figure S3: NMR 1H-indole-3-
carboxaldehyde.
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